Jazz Pharma Consensus Deemed Low and 4 Stock Analyses Making Rounds
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): Current Price: $56.57
According to Lazard Capital, consensus expectations for Jazz Pharmaceuticals have been too low after the company’s Xyrem price increase last week. The firm reiterates its Buy rating and an $87 price target on the stock.
Helmerich & Payne Inc. (NYSE:HP): Current Price: $64.08
Stephens made the decision to raise its price target on Helmerich & Payne after it reported stronger Q1 results than predicted. The firm decided to keep its Equal Weight rating on the stock.
HCA Holdings Inc (NYSE:HCA): Current Price: $38.34
Jefferies has stated that HCA Holdings shares are likely to perform well during 2013 given expectations for healthcare reform implementation during 2014. The firm decided to keep its Buy rating and increase its price target to $45 on the stock.
Cisco Systems, Inc. (NASDAQ:CSCO): Current Price: $21.09
After the firm’s checks, Oppenheimer is convinced that Cisco is well-positioned to report stronger results for its January quarter than predicted. The firm is convinced that U.S. demand for the company’s products has shown improvement, and it keeps an Outperform rating, but raises its target to $24 from $22 on the stock.
Heartware International Inc. (NASDAQ:HTWR): Current Price: $90.47
According to Oppenheimer, HeartWare will provide 2013 guidance on February 5, and the firm has stated that the company is traditionally conservative with its first outlook of the year. Oppenheimer is convinced that the company’s launch of HVAD is solid although it believes that it’s possible that the stock may be muted during the near-term. The firm thinks that the stock will have various positive catalysts later in the year, and it recommends buying the shares on any pullbacks.